CSL Saham

CSL Rule of 40

Delisted·19 Jun 2026

Rule of 40 dari CSL (CSL.AX) pada 15 Agu 2026 adalah 31,50 %. Tahun sebelumnya, Rule of 40 adalah 36,95 % — perubahan sebesar -14,75% (lebih rendah).

Rule of 40

31,50 %

YoY

-14,75%

Terakhir Diperbarui:

Rule of 40 dari CSL adalah 2026 31,50 % . Rule of 40 dari CSL adalah 2025 36,95 % . Menurun -14,75% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

CSL Analisis saham

Apa yang dilakukan CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham CSL

Rule of 40 CSL adalah 31,50 % pada tahun 2026.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Rule of 40 CSL sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Rule of 40 menyatakan bahwa tingkat pertumbuhan pendapatan perusahaan ditambah margin laba harus melebihi 40%. Ini banyak digunakan untuk mengevaluasi perusahaan SaaS dan pertumbuhan tinggi.

Access this data via the Eulerpool API

Kualitas — CSL

Semua Metrik Kunci — CSL